- Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, was developed by Incyte Corp INCY and launched in collaboration with Eli Lilly And Co LLY, received FDA approval for hair loss disorder known as alopecia areata (AA).
- Olumiant was first approved for the treatment of rheumatoid arthritis (RA) in 2018.
- The above nod is expected to provide a template for Equillium Inc EQ EQ-101 in this indication, says HC Wainwright.
- Related: Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy.
- The analysts write that the size and design of the pivotal trials with baricitinib in AA are manageable and should prove relatively cost-effective if EQ-101 is advanced into Phase 3 studies.
- EQ-101's niche to exploit impact on AA may be eclipsed even after clinically meaningful and competitive data, as JAK inhibitors have come under scrutiny for safety reasons.
- The analysts reiterate a Buy rating and a price target of $15 per share on EQ.
- "From our vantage point, investors continue to ignore the potential of the Bioniz portfolio that Equillium acquired earlier this year, including EQ-101," writes HC Wainwright.
- Related: Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition.
- Price Action: EQ shares are up 2.97% at $2.08 during the market session on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.